An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.
Sponsor: Dana-Farber Cancer Institute
This PHASE1/PHASE2 trial investigates Breast Cancer and is currently completed. Dana-Farber Cancer Institute leads this study, which shows 14 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
14 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2021 — Jul 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
▶ Show 9 earlier versions
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Aug 2019 — May 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Mar 2019 — Aug 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Mar 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Apr 2017 — Jan 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Apr 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Mar 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Dana-Farber Cancer Institute
- Novartis
For direct contact, visit the study record on ClinicalTrials.gov .